Gut microbiota and metabolomic characteristics associated with metabolic syndrome in post-cholecystectomy patients: a retrospective cross-sectional study - Report - MDSpire

Gut microbiota and metabolomic characteristics associated with metabolic syndrome in post-cholecystectomy patients: a retrospective cross-sectional study

  • By

  • Yue Lou

  • Xiangping Wang

  • June 22, 2026

  • 0 min

Share

Association of Gut Microbiota and Metabolomic Profiles with Metabolic Syndrome

Overview

This study investigates the differences in gut microbiota and metabolomic profiles between post-cholecystectomy patients with and without metabolic syndrome. Findings indicate that metabolic syndrome is associated with distinct microbial and metabolomic alterations linked to inflammatory and metabolic indicators.

Background

Cholecystectomy is a common surgical procedure that can lead to long-term complications, particularly in patients with metabolic syndrome. Understanding the interplay between gut microbiota, bile acid metabolism, and metabolic syndrome is crucial for managing postoperative outcomes and associated metabolic risks.

Data Highlights

ParameterMS GroupNon-MS Group
Chao1 RichnessLowerHigher
Firmicutes/Bacteroidetes RatioLowerHigher
Prevotella AbundanceIncreasedDecreased
Bacteroides AbundanceReducedHigher
Short-Chain Fatty AcidsDiminishedNormal

Key Findings

  • Patients with metabolic syndrome exhibited reduced microbial richness as indicated by lower Chao1 richness.
  • The Firmicutes/Bacteroidetes ratio was lower in the metabolic syndrome group.
  • Increased abundance of Prevotella and reduced abundance of Bacteroides, Faecalibacterium, and Roseburia were observed in the metabolic syndrome group.
  • Metabolomic analysis showed elevated secondary bile acids and diminished short-chain fatty acids, particularly butyrate, in the metabolic syndrome group.
  • Correlation analysis linked microbiota changes to inflammatory markers and adverse metabolic indices.

Clinical Implications

The distinct gut microbial and metabolomic profiles in post-cholecystectomy patients with metabolic syndrome highlight the need for further investigation into these associations.

Conclusion

This study reveals significant differences in gut microbiota and metabolomic profiles between post-cholecystectomy patients with and without metabolic syndrome.

Related Resources & Content

  1. Xu et al., Journal of Gastrointestinal Surgery, 2025 -- Evaluating the Necessity of Cholecystectomy in Cholelithiasis: Is Surgical Intervention Always the Optimal Choice?
  2. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome, JACC, 2026
  3. Postcholecystectomy Gut Microbiome Changes and the Clinical Impact: A Systematic Review With Narrative Synthesis, PubMed, 2025
  4. Obesity Surgery — Comparative Analysis of Sleeve Gastrectomy and Gastric Bypass Effects on Metabolic, Gut Microbiome, and Immune-Inflammatory Profiles in Patients
  5. Frontiers in Medicine — Gut-brain axis disruption, intestinal barrier damage, and systemic inflammation as predictors of POCD after cholecystectomy: a nested case-control study
  6. Obesity Surgery — Identifying Risk Factors for Cholecystectomy Following Laparoscopic Roux-En-Y Gastric Bypass Surgery
  7. Comparative Analysis of Sleeve Gastrectomy and Gastric Bypass Effects on Metabolic, Gut Microbiome, and Immune-Inflammatory Profiles in Patients
  8. Gut-brain axis disruption, intestinal barrier damage, and systemic inflammation as predictors of POCD after cholecystectomy: a nested case-control study
  9. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | JACC
  10. Postcholecystectomy Gut Microbiome Changes and the Clinical Impact: A Systematic Review With Narrative Synthesis - PubMed
  11. The bile acid-gut microbiota axis: A central hub for physiological regulation and a novel therapeutic target for metabolic diseases - ScienceDirect

Original Source(s)

Related Content